The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
In June 1884, Jan Gerrit Bantjes (1843–1914) discovered signs of gold at Vogelstruisfontein (the first gold sold directly to Cecil Rhodes at Bantjes's camp for £3,000) followed in September by the Struben brothers at Wilgespruit near Roodepoort which started the Witwatersrand Gold Rush and modern-day Johannesburg. The first gold mines of the Witwatersrand were the Bantjes Consolidated Mines. By 1886 it was clear that there were massive deposits of gold in the main reef. Increasingly Uitlanders (non-Afrikaner European expatriates and settlers, mainly from Britain but also including other Europeans, Americans and Australians), had come into the republic in search of employment and fortune. The discovery of gold made the Transvaal overnight the richest and potentially the most powerful nation in southern Africa, but it attracted so many Uitlanders (in 1896 approximately 60,000) that they quickly outnumbered the Boers (approximately 30,000 white male Boers). Fearful of the Transvaal's losing independence and becoming a British colony, the Boer government adopted policies of protectionism and exclusion, to include restrictions requiring Uitlanders to be resident for at least four years in the Transvaal to obtain the franchise, or right to vote. They heavily taxed the growing gold mining industry which was more dominated by incoming Uitlanders. Due to this taxation, the Uitlanders became increasingly resentful and aggrieved about the lack of representation.
The corselet, also known as a breastplate or gorget, is an oval or rectangular collar-piece resting on the shoulders, chest and back, to support the helmet and seal it to the suit, usually made from copper and brass, but occasionally steel. The helmet is usually connected to the suit by placing the holes around the rubberised collar of the suit over bolts along the rim of the corselet, and then clamping the brass straps known as brailes against the collar with wing nuts to press the rubber against the metal of the corselet rim to make a water-tight seal. An alternative method was to bolt the bonnet to the corselet over a rubber collar bonded to the top of the suit. Most six and twelve bolt bonnets are joined to the corselet by 1/8th turn interrupted thread. The helmet neck thread is placed onto the neck of the corselet facing the divers left front, where the threads do not engage, and then rotated forward, engaging the thread and seating on a leather gasket to make a watertight seal. The helmet usually has a safety lock which prevents the bonnet from rotating back and separating underwater. Other styles of connection are also used, with the joint secured by clamps or bolts (usually three).
Levamisole, sold under the brand name Ergamisol among others, is a medication used to treat parasitic worm infections, specifically ascariasis and hookworm infections. It is taken by mouth. Side effects may include abdominal pain, vomiting, headache, and dizziness. Use is not recommended during breastfeeding or the third trimester of pregnancy. Serious side effects may include an increased risk of infection. It belongs to the anthelmintic class of medications. Levamisole was invented in 1966 in Belgium by Janssen Pharmaceuticals. It is on the World Health Organization's List of Essential Medicines. Levamisole is also used as a dewormer for cattle. It is also often used as a cutting agent in illegal cocaine. In February 2026, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that medicines containing levamisole be withdrawn from the EU market. This follows an EU-wide review which concluded that the benefits of these medicines no longer outweigh their risks for the treatment of parasitic worm infections in adults and children.
A functional beverage is a drink marketed to highlight specific product ingredients or supposed health effects. Beverages marketed as "functional" include dairy drinks, sports and performance drinks, energy drinks, ready-to-drink teas, kombucha, "smart" drinks, fortified fruit drinks, plant milks, and enhanced water. Although these beverages may serve to hydrate a consumer, they have no proven health effects, and accordingly appear not to be "functional". For example, there is no good clinical evidence that kombucha provides any benefit to human health.
The parties of the Weimar Coalition (Social Democrats, Centre and the left-liberal German Democratic Party (DDP)) were the base of the Weimar Republic but lost their majority in the 1920 elections. After this, majority governments were rare as they required the support of the Weimar Coalition and the national liberal German People's Party (DVP). Social Democrats and DVP found it hard to agree on economic policy while Social Democrats disagreed with the Centre Party on issues like religious schools or a nationwide Concordat with the Holy See. Following the 1920 elections, the Centre's Constantin Fehrenbach formed a minority government in a coalition with the DDP and the DVP. In May 1921 the Weimar Coalition once again joined forces with the Centre's Joseph Wirth as Chancellor, but this minority government collapsed again in November 1922. After this, the Centre participated in the non-affiliated Wilhelm Cuno's "government of the economy", together with both liberal parties and the Bavarian People's Party (BVP). In August 1923, the DVP's Gustav Stresemann formed a Grand Coalition administration, comprising the Centre, both Liberal parties and the Social Democrats, which lasted until November, when the Social Democrats left the coalition and the Centre's Wilhelm Marx became chancellor of a cabinet of the remaining parties. In January 1925 the non-affiliated Hans Luther was appointed chancellor and formed a coalition between the Centre, both Liberal parties, the BVP and, for the first time, the right-wing German National People's Party (DNVP).
Sources: en.wikipedia.org
FAD can be reduced to FADH2 through the addition of 2 H+ and 2 e−. FADH2 can also be oxidized by the loss of 1 H+ and 1 e− to form FADH. The FAD form can be recreated through the further loss of 1 H+ and 1 e−. FAD formation can also occur through the reduction and dehydration of flavin-N(5)-oxide. Based on the oxidation state, flavins take specific colors when in aqueous solution. Flavin-N(5)-oxide (super oxidized) is yellow-orange, FAD (fully oxidized) is yellow, FADH (half reduced) is either blue or red based on the pH, and the fully reduced form is colorless. Changing the form can have a large impact on other chemical properties. For example, FAD, the fully oxidized form is subject to nucleophilic attack, the fully reduced form, FADH2 has high polarizability, while the half reduced form is unstable in aqueous solution. FAD is an aromatic ring system, whereas FADH2 is not. This means that FADH2 is significantly higher in energy, without the stabilization through resonance that the aromatic structure provides. FADH2 is an energy-carrying molecule, because, once oxidized it regains aromaticity and releases the energy represented by this stabilization. The spectroscopic properties of FAD and its variants allows for reaction monitoring by use of UV-VIS absorption and fluorescence spectroscopies. Each form of FAD has distinct absorbance spectra, making for easy observation of changes in oxidation state. A major local absorbance maximum for FAD is observed at 450 nm, with an extinction coefficient of 11,300 M−1 cm−1.
Chymosin or rennin is a protease found in rennet. It is an aspartic endopeptidase belonging to MEROPS A1 family. It is produced by newborn ruminant animals in the lining of the abomasum to curdle the milk they ingest, allowing a longer residence in the bowels and better absorption. It is widely used in the production of cheese. Historically, chymosin was obtained by extracting it from the stomachs of slaughtered calves. Today, most commercial chymosin used in cheese production is produced recombinantly in Escherichia coli, Aspergillus niger var. awamori, and Kluyveromyces lactis.
A glucose tolerance test requires IV or oral administration of a sugar. Multiple blood draws are then performed to measure blood glucose and insulin levels over time. The area under this curve is the best indicator of insulin resistance, but it may also be evaluated just based on the peak value and time to return to baseline. The combined glucose-insulin test requires less time to perform than the glucose tolerance test. It involves a baseline blood draw, followed by an IV injection of dextrose, and then an injection of insulin. Blood glucose is measured every 10–15 minutes over the course of 2.5 hours. Samples are evaluated for time to return to baseline blood glucose levels, and insulin blood concentration. Elevated insulin concentration suggest insulin resistance. Rarely, this test can result in hypoglycemia, which requires administration of IV dextrose to correct.
DNA gel electrophoresis is usually performed for analytical purposes, often after amplification of DNA via polymerase chain reaction (PCR), but may be used as a preparative technique for other methods such as mass spectrometry, RFLP, PCR, cloning, DNA sequencing, or Southern blotting for further characterization.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.